Sparta Surgical
This article was originally published in The Gray Sheet
Executive Summary
Pleasanton, California-based surgical and electrotherapy products manufacturer files a registration statement for a public offering of 1,250,000 units, each consisting of four shares of common stock and three Series B redeemable common stock purchase warrants. Net proceeds from the offering will be used for repayment of debt, purchase of equipment, research and development expense, marketing expenses and working capital, the company says. Coleman and Company Securities is the managing underwriter
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.